Skip Nav Destination
Issues
1 November 2012
-
Cover Image
Cover Image
Miyamoto and colleagues noninvasively assayed androgen receptor (AR) signaling activity in patients with prostate cancer by measuring levels of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) in single circulating tumor cells (CTC). The CTCs of untreated patients showed an “AR-on” (PSA+/PSMA−) signature that switched to an “AR-off” (PSA−/PSMA+) signature after androgen deprivation therapy, but the CTCs of patients with castration-resistant prostate cancer (CRPC) were heterogeneous and had “AR-on,” “AR-off,” and “AR-mixed” (PSA+/PSMA+) signatures. The presence of “AR-mixed” CTCs was associated with a poor response to abiraterone acetate, suggesting that monitoring of AR signaling in CTCs may guide use of secondary hormonal therapies in patients with CRPC. For details, please see the article by Miyamoto and colleagues on page 995. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
Review
Research Brief
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
David T. Miyamoto; Richard J. Lee; Shannon L. Stott; David T. Ting; Ben S. Wittner; Matthew Ulman; Malgorzata E. Smas; Jenna B. Lord; Brian W. Brannigan; Julie Trautwein; Neil H. Bander; Chin-Lee Wu; Lecia V. Sequist; Matthew R. Smith; Sridhar Ramaswamy; Mehmet Toner; Shyamala Maheswaran; Daniel A. Haber
Research Articles
Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Huimin Geng; Sarah Brennan; Thomas A. Milne; Wei-Yi Chen; Yushan Li; Christian Hurtz; Soo-Mi Kweon; Lynette Zickl; Seyedmehdi Shojaee; Donna Neuberg; Chuanxin Huang; Debabrata Biswas; Yuan Xin; Janis Racevskis; Rhett P. Ketterling; Selina M. Luger; Hillard Lazarus; Martin S. Tallman; Jacob M. Rowe; Mark R. Litzow; Monica L. Guzman; C. David Allis; Robert G. Roeder; Markus Müschen; Elisabeth Paietta; Olivier Elemento; Ari M. Melnick
Genome-wide DNA Methylation Events in TMPRSS2–ERG Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with miR-26a Hypermethylation
Stefan T. Börno; Axel Fischer; Martin Kerick; Maria Fälth; Mark Laible; Jan C. Brase; Ruprecht Kuner; Andreas Dahl; Christina Grimm; Behnam Sayanjali; Melanie Isau; Christina Röhr; Andrea Wunderlich; Bernd Timmermann; Rainer Claus; Christoph Plass; Markus Graefen; Ronald Simon; Francesca Demichelis; Mark A. Rubin; Guido Sauter; Thorsten Schlomm; Holger Sültmann; Hans Lehrach; Michal R. Schweiger
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim; Celina García-García; Violeta Serra; Lei He; Kristine Torres-Lockhart; Aleix Prat; Pilar Anton; Patricia Cozar; Marta Guzmán; Judit Grueso; Olga Rodríguez; Maria Teresa Calvo; Claudia Aura; Orland Díez; Isabel T. Rubio; José Pérez; Jordi Rodón; Javier Cortés; Leif W. Ellisen; Maurizio Scaltriti; José Baselga
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar; Laura N. Burga; Hai Hu; Elaine P. Lunsford; Yasir H. Ibrahim; Judith Balmañà; Anbazhagan Rajendran; Antonella Papa; Katherine Spencer; Costas A. Lyssiotis; Caterina Nardella; Pier Paolo Pandolfi; José Baselga; Ralph Scully; John M. Asara; Lewis C. Cantley; Gerburg M. Wulf
News in Brief
News in Depth
Research Watch
Breast Cancer
Clinical Trials
DNA Repair
Drug Development
Immunotherapy
Inflammation
Leukemia
Lung Cancer
Lymphoma
Melanoma
Metabolism
Oncogenes
Pancreatic Cancer
Prostate Cancer
Signaling
Surveillance
Systems Biology
Targeted Therapy
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.